Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

(2014) P. O'Connor et al.   NEUROLOGY

JC virus antibody status underestimates infection rates

(2013) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

(2013) Peter Lee et al.   JOURNAL OF CLINICAL VIROLOGY

Changes to anti-JCV antibody levels in a Swedish national MS cohort

(2013) Clemens Warnke et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

(2013) Olivier Outteryck et al.   Multiple Sclerosis Journal

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia

(2013) K. Masutani et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

(2013) N. Schwab et al.   NEUROLOGY

JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis

(2013) Eugene O. Major et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy

(2012) Kazuo Nakamichi et al.   ARCHIVES OF VIROLOGY

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

(2012) Olivier Outteryck et al.   JOURNAL OF NEUROLOGY

Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)

(2012) C. Bozic et al.   NEUROLOGY

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

High Levels of Antibodies Against Merkel Cell Polyomavirus Identify a Subset of Patients With Merkel Cell Carcinoma With Better Clinical Outcome

(2011) Antoine Touzé et al.   JOURNAL OF CLINICAL ONCOLOGY

Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer

(2011) Diana V. Pastrana et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

BK virus antibody titers and intensity of infections after renal transplantation

(2008) Daniel L. Bohl et al.   JOURNAL OF CLINICAL VIROLOGY

Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology

(2008) Rainer Gosert et al.   JOURNAL OF EXPERIMENTAL MEDICINE